These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26661118)

  • 1. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
    J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
    Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
    Mahdi H; Xiu J; Reddy SK; DeBernardo R
    J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
    El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
    Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
    Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
    Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
    Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
    Horwitz E; Stein I; Andreozzi M; Nemeth J; Shoham A; Pappo O; Schweitzer N; Tornillo L; Kanarek N; Quagliata L; Zreik F; Porat RM; Finkelstein R; Reuter H; Koschny R; Ganten T; Mogler C; Shibolet O; Hess J; Breuhahn K; Grunewald M; Schirmacher P; Vogel A; Terracciano L; Angel P; Ben-Neriah Y; Pikarsky E
    Cancer Discov; 2014 Jun; 4(6):730-43. PubMed ID: 24687604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
    Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
    Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
    Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
    Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
    Chong DQ; Tan IB; Choo SP; Toh HC
    Contemp Clin Trials; 2013 Nov; 36(2):605-15. PubMed ID: 23591326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
    Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.
    Subbiah IM; Falchook GS; Kaseb AO; Hess KR; Tsimberidou AM; Fu S; Subbiah V; Hong DS; Naing A; Piha-Paul SA; Akmal O; Janku F; Kurzrock R
    Oncotarget; 2015 Sep; 6(29):28453-62. PubMed ID: 26164085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor heterogeneity in hepatocellular carcinoma.
    Friemel J; Rechsteiner M; Frick L; Böhm F; Struckmann K; Egger M; Moch H; Heikenwalder M; Weber A
    Clin Cancer Res; 2015 Apr; 21(8):1951-61. PubMed ID: 25248380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular targeted agent for hepatocellular carcinoma].
    Ueshima K; Kudo M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():457-62. PubMed ID: 23520633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.